Results 191 to 200 of about 34,705 (216)
Some of the next articles are maybe not open access.
Muscular weakness in the mdx mouse
Journal of the Neurological Sciences, 1993mdx mice are believed to be virtually free from neuromuscular symptoms, despite the presence of a degenerative/regenerative process that involves all skeletal muscles. We analyzed both the spontaneous motility and treadmill motor activity of mdx mice aged 15 days to 6 months.
Muntoni F. +4 more
openaire +3 more sources
Running endurance abnormality in mdx mice
Muscle & Nerve, 2002AbstractThe mdx mouse lacks dystrophin and has histological features of Duchenne muscular dystrophy but little weakness in the first year of life. We report here an early deficit in voluntary wheel running, as assayed with a computerized wheel. All mdx mice showed an intermittent running pattern, in contrast to the continuous running seen in controls ...
Hajime, Hara +5 more
openaire +2 more sources
Text-to-MDX: LLM-Assisted Generation of MDX Queries from User Questions
MDX (MultiDimensional Expressions) is the standard language for querying multidimensional data in OLAP systems, but its complex syntax poses challenges for non-expert users. While a lot of research has focused on natural language interfaces for SQL, little attention has been given to MDX. This paper explores the potential of Large Language Models (LLMs)Sandro Bimonte, Stefano Rizzi
openaire +2 more sources
2002
MDX is the key to unlocking all of the advanced capabilities of Analysis Services, so once you go beyond building basic cubes and want to add business logic to the cube, you really start to need MDX.
Mark Whitehorn +2 more
openaire +1 more source
MDX is the key to unlocking all of the advanced capabilities of Analysis Services, so once you go beyond building basic cubes and want to add business logic to the cube, you really start to need MDX.
Mark Whitehorn +2 more
openaire +1 more source
Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2000
A.I Chechin, C.D Prokudaylo
openaire +1 more source
A.I Chechin, C.D Prokudaylo
openaire +1 more source
2002
The first edition of this book (18 chapters long) was written as an easy introduction to MDX. Assuming we succeeded in this task, by now you should be over that initial steep learning curve. So, when we came to add this extra material for the second edition we felt that it was appropriate to change gear a little and look at some more advanced topics ...
Mark Whitehorn +2 more
openaire +1 more source
The first edition of this book (18 chapters long) was written as an easy introduction to MDX. Assuming we succeeded in this task, by now you should be over that initial steep learning curve. So, when we came to add this extra material for the second edition we felt that it was appropriate to change gear a little and look at some more advanced topics ...
Mark Whitehorn +2 more
openaire +1 more source
2012
Multidimensional Expressions (MDX) is a Microsoft-owned specification, not an open standard language. But, it has been adopted by many vendors and is considered an industry standard for querying and manipulating multidimensional data for SSAS.
Randal Root, Caryn Mason
openaire +1 more source
Multidimensional Expressions (MDX) is a Microsoft-owned specification, not an open standard language. But, it has been adopted by many vendors and is considered an industry standard for querying and manipulating multidimensional data for SSAS.
Randal Root, Caryn Mason
openaire +1 more source
Personalization of MDX queries
2006Answers of OLAP queries often cannot be visualized entirely and the user has to navigate through them to find relevant facts. One possible way to solve this problem is to personalize the queries. The basic idea behind the process of query personalization is that different users may find and see the facts they prefer without having to navigate.
Bellatreche, Ladjel +3 more
openaire +1 more source
IDrugs : the investigational drugs journal, 2010
Medarex is developing MDX-RA, an immunotoxin, for the potential prevention of secondary cataracts. It entered phase III clinical trials in December 1997. The phase III studies will involve 680 patients undergoing primary cataract surgery at approximately 60 sites in the US [272814].
openaire +1 more source
Medarex is developing MDX-RA, an immunotoxin, for the potential prevention of secondary cataracts. It entered phase III clinical trials in December 1997. The phase III studies will involve 680 patients undergoing primary cataract surgery at approximately 60 sites in the US [272814].
openaire +1 more source